Tiletamine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Tiletamine
Accession Number
DB11549
Type
Small Molecule
Groups
Vet approved
Description

This drug is a dissociative anesthetic agent that falls under the drug category of NMDA receptor antagonists. Tiletamine is chemically similar to another dissociative anesthetic, ketamine. Tiletamine hydrochloride, the salt form, exists as odorless white crystals.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Tiletamine hydrochloride99TAQ2QWJI14176-50-2ZUYKJZQOPXDNOK-UHFFFAOYSA-N
Categories
UNII
2YFC543249
CAS number
14176-49-9
Weight
Average: 223.33
Monoisotopic: 223.103085345
Chemical Formula
C12H17NOS
InChI Key
QAXBVGVYDCAVLV-UHFFFAOYSA-N
InChI
InChI=1S/C12H17NOS/c1-2-13-12(11-7-5-9-15-11)8-4-3-6-10(12)14/h5,7,9,13H,2-4,6,8H2,1H3
IUPAC Name
2-(ethylamino)-2-(thiophen-2-yl)cyclohexan-1-one
SMILES
CCNC1(CCCCC1=O)C1=CC=CS1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3-isobutyl-1-methyl-7H-xanthineTiletamine may increase the excretion rate of 3-isobutyl-1-methyl-7H-xanthine which could result in a lower serum level and potentially a reduction in efficacy.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Tiletamine.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Tiletamine.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with 5-methoxy-N,N-dimethyltryptamine.
6-O-benzylguanineTiletamine may increase the excretion rate of 6-O-benzylguanine which could result in a lower serum level and potentially a reduction in efficacy.
7-DeazaguanineTiletamine may increase the excretion rate of 7-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tiletamine.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Tiletamine.
7,9-DimethylguanineTiletamine may increase the excretion rate of 7,9-Dimethylguanine which could result in a lower serum level and potentially a reduction in efficacy.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Natalini CC, Alves SD, Guedes AG, Polydoro AS, Brondani JT, Bopp S: Epidural administration of tiletamine/zolazepam in horses. Vet Anaesth Analg. 2004 Apr;31(2):79-85. [PubMed:15053744]
  2. Wilson RP, Zagon IS, Larach DR, Lang CM: Cardiovascular and respiratory effects of tiletamine-zolazepam. Pharmacol Biochem Behav. 1993 Jan;44(1):1-8. [PubMed:8430114]
  3. Calderwood HW, Klide AM, Cohn BB, Soma LR: Cardiorespiratory effects of tiletamine in cats. Am J Vet Res. 1971 Oct;32(10):1511-5. [PubMed:5115540]
  4. Hubbell JA, Bednarski RM, Muir WW: Xylazine and tiletamine-zolazepam anesthesia in horses. Am J Vet Res. 1989 May;50(5):737-42. [PubMed:2729719]
  5. Cattet MR, Caulkett NA, Lunn NJ: Anesthesia of polar bears using xylazine-zolazepam-tiletamine or zolazepam-tiletamine. J Wildl Dis. 2003 Jul;39(3):655-64. [PubMed:14567228]
  6. Lin HC, Wallace SS, Tyler JW, Robbins RL, Thurmon JC, Wolfe DF: Comparison of tiletamine-zolazepam-ketamine and tiletamine-zolazepam-ketamine-xylazine anaesthesia in sheep. Aust Vet J. 1994 Aug;71(8):239-42. [PubMed:7986185]
  7. Fernandez-Moran J, Palomeque J, Peinado VI: Medetomidine/tiletamine/zolazepam and xylazine/tiletamine/zolazepam combinations for immobilization of fallow deer (Cervus dama). J Zoo Wildl Med. 2000 Mar;31(1):62-4. [PubMed:10884126]
  8. Caulkett NA, Cattet MR, Cantwell S, Cool N, Olsen W: Anesthesia of wood bison with medetomidine-zolazepam/tiletamine and xylazine-zolazepam/tiletamine combinations. Can Vet J. 2000 Jan;41(1):49-53. [PubMed:10642872]
  9. Selmi AL, Mendes GM, Figueiredo JP, Guimaraes FB, Selmi GR, Bernal FE, McMannus C, Paludo GR: Chemical restraint of peccaries with tiletamine/zolazepam and xylazine or tiletamine/zolazepam and butorphanol. Vet Anaesth Analg. 2003 Jan;30(1):24-9. [PubMed:14498914]
  10. Cattet MR, Caulkett NA, Polischuk SC, Ramsay MA: Anesthesia of polar bears (Ursus maritimus) with zolazepam-tiletamine, medetomidine-ketamine, and medetomidine-zolazepam-tiletamine. J Zoo Wildl Med. 1999 Sep;30(3):354-60. [PubMed:10572857]
External Links
KEGG Drug
D08596
ChemSpider
24714
ChEBI
94356
ChEMBL
CHEMBL2110703
Wikipedia
Tiletamine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0965 mg/mLALOGPS
logP2.58ALOGPS
logP3.01ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)18.69ChemAxon
pKa (Strongest Basic)7.56ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area29.1 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity62.39 m3·mol-1ChemAxon
Polarizability24.65 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Aralkylamines
Alternative Parents
Thiophenes / Heteroaromatic compounds / Cyclic ketones / Dialkylamines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Aralkylamine / Heteroaromatic compound / Thiophene / Cyclic ketone / Ketone / Organoheterocyclic compound / Secondary amine / Secondary aliphatic amine / Organic oxygen compound / Organopnictogen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on February 26, 2016 10:43 / Updated on June 04, 2019 07:23